May 29, 2008 - Aphios Corporation today announced that it has been awarded a Japanese Patent No. 4,107,680, issued on April 11, 2008, for its phospholipid nanosomes technology platform for the encapsulation of hydrophobic drugs.
Phospholipid nanosomes are small, uniform liposomes manufactured utilizing SuperFluids(TM). SuperFluids(TM) are normally gases which, when compressed, exhibit enhanced solvation, penetration and expansive properties. These fluids are reverse-engineered to form phospholipid nanosomes for encapsulating and improving the delivery of protein therapeutics, vaccine antigens and sRNAi molecules as well as small molecule therapeutics and hydrophobic drugs such as paclitaxel, camptothecin and bryostatin 1. Dr. Castor, the inventor of this technology platform, points out "this technology does not utilize organic solvents that could be harmful to the therapeutic, the recipient and/or the environment and is rapid, broadly-applicable and scalable while enhancing drug delivery."
The details can be read here.
No comments:
Post a Comment